CD274 and non-small cell lung carcinoma: Recommendations:PD-L1 expression by IHC is currently accepted as the only validated biomarker for anti-PD-1/PD-L1 therapy in unresectable locally advanced (based on a controversial EMA decision) and advanced NSCLC [60].